Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trialZoltán Bánki, Janine Kimpel, Helena Schäfer et al.|EBioMedicine|2022Cited by 38
Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotypeZoltán Bánki, Krishna Das, Andreas Aufschnaiter et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 9